TY - JOUR
T1 - Advances in Rejection Management
T2 - Prevention and Treatment
AU - Harrington, Claire R.
AU - Yang, Guang Yu
AU - Levitsky, Josh
N1 - Funding Information:
Dr J. Levitsky is a consultant, stockholder, and recipient of research funds from Viracor, Eurofins, and Transplant Genomics Inc.; Dr J. Levitsky is a consultant, speaker, and recipient of research funds from Novartis. Dr C.R. Harrington and Dr G-Y. Yang have nothing to disclose.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/2
Y1 - 2021/2
N2 - Extended survival of liver transplant recipients has brought rejection management to the forefront of liver transplant research. This article discusses T-cell–mediated rejection, antibody-mediated rejection, and chronic rejection. We focus on the prevention and then discuss treatment options. Future directions of rejection management include biomarkers of rejection, which may allow for monitoring of patients who are considered high risk for rejection and detection of rejection before there is any clinical evidence to improve graft and patient survival. With improved graft life and survival of liver transplant recipients, the new frontier of rejection management focuses on immunosuppression minimization, withdrawal, and personalization.
AB - Extended survival of liver transplant recipients has brought rejection management to the forefront of liver transplant research. This article discusses T-cell–mediated rejection, antibody-mediated rejection, and chronic rejection. We focus on the prevention and then discuss treatment options. Future directions of rejection management include biomarkers of rejection, which may allow for monitoring of patients who are considered high risk for rejection and detection of rejection before there is any clinical evidence to improve graft and patient survival. With improved graft life and survival of liver transplant recipients, the new frontier of rejection management focuses on immunosuppression minimization, withdrawal, and personalization.
KW - Antibody-mediated rejection
KW - Biomarkers of rejection
KW - Immunosuppression minimization
KW - T-cell mediated rejection
KW - Tolerance
UR - http://www.scopus.com/inward/record.url?scp=85094116571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094116571&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2020.08.003
DO - 10.1016/j.cld.2020.08.003
M3 - Review article
C2 - 33978583
AN - SCOPUS:85094116571
SN - 1089-3261
VL - 25
SP - 53
EP - 72
JO - Clinics in liver disease
JF - Clinics in liver disease
IS - 1
ER -